Quick summary
Epitide (Palmitoyl Tripeptide-38 / MATRIXYL synthe'6) stimulates synthesis of six ECM components simultaneously: collagen I, III, IV, fibronectin, hyaluronic acid, and laminin-5. Used in premium anti-aging and lip-plumping products.
Overview
Epitide, commercially known as MATRIXYL synthe'6 (Palmitoyl Tripeptide-38), is a matrikine-mimetic lipopeptide developed by Sederma. The sequence Pal-Lys-Met(O2)-Lys was inspired by a natural tripeptide found in collagen VI and laminin. It stimulates synthesis of six key extracellular matrix components simultaneously, earning its name. It is used in premium anti-aging skincare formulations targeting fine lines, deep wrinkles, and loss of skin volume, and also finds application in lip-plumping products under the Volulip trade name.
Mechanism of action
Palmitoyl Tripeptide-38 acts as a matrikine — a bioactive peptide fragment derived from ECM proteins — that signals fibroblasts and keratinocytes to upregulate production of six dermal matrix constituents: collagen I, collagen III, collagen IV, fibronectin, hyaluronic acid, and laminin-5. It modulates MMP activity to reduce collagen degradation while simultaneously driving new ECM synthesis through activation of TGF-β and integrin-mediated pathways. The palmitoyl lipid tail enhances skin penetration through the lipid-rich stratum corneum and tethers the peptide to cell membranes, increasing dwell time at the target receptor site. This broad-spectrum ECM stimulation results in improved dermal thickness, elasticity, and hydration.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| anti-aging dermal matrix repair application | topical | 1–5 % | once or twice daily | Formulated at 1–5% in serums, creams, and lip treatments. Stable across pH 4.5–7.5. Compatible with most cosmetic actives. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Sederma-sponsored clinical studies report statistically significant reductions in wrinkle volume, improvements in skin tone uniformity, and increased skin density after 28–56 days of twice-daily topical use. In vitro studies on fibroblast and keratinocyte cultures confirm upregulation of all six ECM targets at the mRNA and protein level. A 2025 PMC review of bioactive oligopeptides in skin regeneration cites Palmitoyl Tripeptide-38 as among the most comprehensively studied matrikine-class cosmetic actives. Independent peer-reviewed clinical validation remains limited as of 2026.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Epitide for synergistic effects.
Legal status
Sold as an OTC cosmetic ingredient globally. Not classified as a drug. No known regulatory restrictions in the US, EU, UK, or equivalent jurisdictions. Widely available in commercial skincare.
Sourcing & access
Research compound
Epitide is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Epitide, commercially known as MATRIXYL synthe'6 (Palmitoyl Tripeptide-38), is a Sederma-developed lipopeptide that stimulates production of six dermal matrix components simultaneously. It is used in premium anti-aging serums and lip-plumping products (Volulip).
Palmitoyl Tripeptide-38 acts as a matrikine that signals fibroblasts and keratinocytes to upregulate collagen I, III, IV, fibronectin, hyaluronic acid, and laminin-5 through TGF-beta and integrin-mediated pathways. It also modulates MMP activity to reduce collagen degradation.
Clinical studies show an excellent tolerability profile. Rare contact irritation at very high concentrations is the only reported adverse effect. It is sold as an OTC cosmetic ingredient globally with no regulatory restrictions.
While most cosmetic peptides target one or two ECM proteins, Epitide stimulates six simultaneously (collagen I, III, IV, fibronectin, hyaluronic acid, and laminin-5), providing broad-spectrum dermal matrix repair in a single ingredient.